Breaking News

Amorfix, Cangene In Oncology Development Pact

December 6, 2012

Will identify antibodies using ProMIS technology

Amorfix Life Sciences has entered into a collaboration with CNJ Holdings, a subsidiary of Cangene Corp., for the identification and development of therapeutic antibodies against disease specific epitopes (DSEs) for oncology indications, using Amorfix's ProMIS discovery technology. The terms were not disclosed. 
"This collaboration represents the ideal situation where two companies come together with complementary expertise, resources and technology in a united effort to identify and develop novel antibody therapeutics for the treatment of cancer," said Dr. Robert Gundel, Amorfix president and chief executive officer. "Establishing partnerships and strategic alliances to accelerate the discovery, development and commercialization of therapeutic antibodies is part of our overall strategy to build our product pipeline."
"We are excited about this collaboration with Amorfix which brings new energy to our R&D pipeline development efforts," said John Sedor, Cangene's president and chief executive officer. "This is an opportunity to leverage our core competencies to accelerate the development of therapeutic antibodies to novel targets in the oncology space.”

Related Contract Manufacturing:

blog comments powered by Disqus
  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research